1. Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. (May 2018) Authors: Gao, Y.; Weenink, B.; van den Bent, M.J.; Erdem-Eraslan, L.; Kros, J.M.; Sillevis Smitt, PAE; Hoang-Xuan, K.; Brandes, A.A.; Vos, M.; Dhermain, F.; Enting, R.; Ryan, G.F.; Chinot, O.; Ben Hassel, M.; van Linde, M.E.; Mason, W.P.; Gijtenbeek, J.M.M.; Balana, C.; von Deimling, A.; Gorlia, Th Journal: European journal of cancer Issue: Volume 94(2018) Page Start: 168 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Standardization of viability assays and high-content live-cell imaging protocols for large-scale drug testing in prostate cancer PDX-derived organoids. (October 2022) Authors: Van Hemelryk, A.; Erkens-Schulze, S.; Lam, L.; Stuurman, D.; de Ridder, C.M.A.; French, P.J.; van Royen, M.E.; van Weerden, W.M. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗